Advanced Lung Failure Management at KIMS Electronic City, Bengaluru

What advanced lung failure means clinically

Advanced lung failure describes end-stage lung disease where standard medical therapy is exhausted or insufficient. Symptoms usually include progressive breathlessness on minimal exertion, exercise intolerance, need for supplemental oxygen, recurrent hospitalisations, weight loss, and reduced quality of life.

The role of a transplant pulmonologist in this space is threefold:

Get the medical therapy right - optimise inhalers, antifibrotics, PAH-specific therapy, oxygen, non-invasive ventilation, comorbidity management
Monitor the trajectory - fixed-interval PFT + DLCO + 6-minute walk + imaging + right heart function to detect the point where transplant becomes appropriate
Manage the transplant journey when it becomes necessary - candidacy evaluation, listing, ECMO bridging, surgery, follow-up

Dr. Manjunath M Negigoudara at KIMS Electronic City, Bengaluru handles all three stages. Multi-disciplinary team review at every case (thoracic surgery, cardiology, radiology, infectious diseases, dietitians, social work).

Conditions treated

Idiopathic pulmonary fibrosis (IPF) and other ILDs

Progressive scarring interstitial lung diseases: IPF, non-specific interstitial pneumonia (NSIP), hypersensitivity pneumonitis (HP), connective-tissue-related ILD (systemic sclerosis, rheumatoid arthritis, dermatomyositis, mixed CTD), sarcoidosis with fibrotic progression.

Treatment: antifibrotic drugs (pirfenidone, nintedanib) to slow FVC decline, oxygen for desaturation, pulmonary rehabilitation, aggressive treatment of GERD (associated with faster ILD progression), and lung transplant referral at GAP Stage II-III or with any serial FVC/DLCO decline. See referral triggers guide.

End-stage COPD and emphysema

Severe airflow obstruction (FEV1 typically below 30% predicted), frequent exacerbations, hypercapnic respiratory failure, oxygen-dependent, and often with pulmonary hypertension developing secondary to hypoxic vasoconstriction. Alpha-1 antitrypsin deficiency in a subset.

Treatment: optimised triple-inhaler regimen (LAMA + LABA + ICS), pulmonary rehab, ambulatory oxygen where indicated, non-invasive ventilation for hypercapnic exacerbations, vaccination (pneumococcal, annual influenza, COVID). Transplant referral at BODE 5-6; list at 7-10.

Pulmonary arterial hypertension (PAH)

Right heart pressures elevated due to primary PAH, secondary to ILD, connective tissue disease, congenital heart disease (Eisenmenger physiology), or chronic thromboembolic disease. Confirmed by right heart catheterisation.

Treatment: PAH-specific therapy (typically triple therapy including a prostacyclin, ERA and PDE-5 inhibitor), diuretics for right heart failure, oxygen, and lung (or heart-lung) transplant when in WHO functional class III-IV despite maximal therapy or when REVEAL risk score is high. Dr. Manjunath M Negigoudara’s ERJ 2023 first-author paper covered PH in Progressive Fibrosing ILD referred for lung transplant.

Post-COVID pulmonary fibrosis and sequelae

A growing referral stream since 2021. Not every patient with post-COVID abnormalities on CT has fibrosis - the Indian working group explicitly recommends dropping the term "post-COVID fibrosis" (90% consensus) in favour of "post-COVID ILD" or "post-COVID pulmonary sequelae" because 80% of patients with CT abnormalities at 105 days show near-complete radiological resolution at one year.

Treatment approach follows the 6-rung ladder: pulmonary rehabilitation first (strongest evidence), inhalers if airway component, corticosteroids for inflammatory pattern, antifibrotic drugs only for a narrow subset (honeycombing + architectural distortion + failed 4 weeks of steroids), oxygen if persistent, transplant assessment only for genuinely progressive end-stage disease. See the full clinician guide.

Post-tuberculosis lung destruction

India-specific significant referral pattern. Bilateral cavitary disease with fibrosis, often with superimposed non-tuberculous mycobacterial infection or aspergilloma. Treatment: complete anti-TB course, treat superimposed infection, pulmonary rehab, oxygen where indicated, transplant evaluation when bilateral disease with FEV1 < 30% or single-lung disease with pulmonary hypertension - and infection has been controlled for at least 6 months.

Bronchiectasis and cystic fibrosis

Suppurative lung disease with recurrent infections. Treatment: airway clearance techniques, targeted antibiotics based on sputum culture, macrolide prophylaxis in selected cases, bronchodilators, treatment of underlying cause (immunodeficiency, ABPA, NTM). Transplant referral at FEV1 < 30% or rapid decline especially in younger female patients, or colonisation with pan-resistant organisms. Always bilateral transplant for suppurative disease.

Refer early, not late

The commonest referral mistake is waiting. Most patients arrive at KIMS Electronic City later than they should. Dr. Manjunath M Negigoudara’s standard advice: if any of the disease-specific thresholds (BODE 5+, GAP II+, PAH refractory to therapy, FEV1 < 30% in suppurative disease) is being approached, refer for consultation. An early conversation usually means "you have 1-2 years of medical therapy left before transplant becomes necessary" - and that gives time to plan, not panic.

The multi-disciplinary team review

Complex advanced lung disease cases are reviewed at a multi-disciplinary team meeting at KIMS Electronic City. Attendees: transplant pulmonology, thoracic surgery, cardiology, radiology, infectious diseases, dietitians, social work. The MDT decides on:

Optimal medical therapy (drug + non-drug)
Whether ECMO would be appropriate for acute decompensation - see ECMO service page
Transplant candidacy - single vs bilateral, urgency, contraindications
Family conversation timing (patients often benefit from a structured "where we are + where we might go" conversation before crisis)

Diagnostic workup we typically arrange

Depending on the underlying disease, the workup usually includes:

PFT with DLCO (spirometry alone is insufficient - diffusion is the abnormality that changes most)
HRCT chest
Six-minute walk test with oximetry
Echocardiogram with right ventricular assessment
Right heart catheterisation (if PH suspected)
Bronchoscopy with BAL and biopsy where indicated
Cryobiopsy for ILD diagnosis where standard TBLB is insufficient - see interventional pulmonology service
Blood work: ANA + ENA panel, RA factor, ACE, precipitins (HP panel), IgG subclasses

Book an advanced lung failure consultation

Bring your most recent HRCT (CD or DICOM images if available - the report alone is not sufficient for our review), any prior PFTs, echocardiogram if available, and a list of current medications with doses. If you have been to other pulmonologists, bring their prescriptions.

For patients too unwell to travel, remote pre-review via WhatsApp is possible - share HRCT, PFT, echo reports as photos or PDFs to +91 79937 41199.

Call +91 79937 41199 · WhatsApp · Book online. Related: lung transplantation, ECMO, who needs a lung transplant.

Frequently asked questions

What is "advanced lung failure" and who does Dr. Manjunath treat?

Advanced lung failure describes end-stage lung disease where standard medical therapy is exhausted or insufficient. Conditions treated: idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, end-stage COPD, pulmonary arterial hypertension, post-COVID pulmonary fibrosis, post-tuberculosis lung destruction, non-CF bronchiectasis, and cystic fibrosis. Managed by Dr. Manjunath M Negigoudara at KIMS Electronic City, often as a bridge toward transplant candidacy where appropriate.

What is the difference between advanced lung failure and needing a transplant?

Not every patient with advanced lung disease needs a transplant. Many live for years on optimised medical therapy - antifibrotics for IPF, triple-therapy inhalers for COPD, PAH-specific therapy for pulmonary hypertension, oxygen where indicated. Dr. Manjunath M Negigoudara's job is to (a) get the medical therapy right, (b) monitor for the point where transplant referral becomes appropriate, and (c) manage the transplant journey if it becomes necessary. See the detailed referral criteria guide.

Do you treat post-COVID lung damage?

Yes. Post-COVID pulmonary sequelae are a growing referral stream. The key clinical positions: (1) most post-COVID lung damage gets better on its own - the Indian working group's 90% consensus is that "post-COVID fibrosis" is often the wrong term; (2) antifibrotic drugs (pirfenidone, nintedanib) did NOT beat placebo in the FIBRO-COVID trial; (3) pulmonary rehabilitation is the treatment with the strongest evidence; (4) transplant is very rare, only for genuinely progressive end-stage disease. See Dr. Manjunath's full post-COVID guide.

What treatment options exist for IPF?

For idiopathic pulmonary fibrosis: (1) antifibrotic drugs (pirfenidone, nintedanib) shown to slow FVC decline; (2) supplemental oxygen where needed; (3) pulmonary rehabilitation; (4) treatment of comorbidities (GERD, PH, OSA); (5) lung transplant when GAP Stage II-III with decline or FVC drops 10%+ or DLCO drops 15%+ over 6 months. Referral for transplant evaluation should be early - not late.

What does end-stage COPD care involve?

Optimised triple-inhaler therapy (LAMA + LABA + ICS), pulmonary rehabilitation, ambulatory oxygen where indicated (PaO2 < 55 mmHg or SpO2 < 88% at rest), non-invasive ventilation for hypercapnic exacerbations, aggressive treatment of infections, and vaccination (pneumococcal, annual flu, COVID). Lung transplant referral is considered when BODE score reaches 5-6, listed at 7-10 (~15-20% four-year survival).

How does the multi-disciplinary team review work?

Complex advanced lung disease cases are reviewed at a multi-disciplinary team meeting at KIMS Electronic City - Dr. Manjunath M Negigoudara (transplant pulmonology), thoracic surgery, cardiology, radiology, infectious diseases, dietitians, and social work. The MDT decides on optimal medical therapy, transplant candidacy, ECMO decisions, and family conversation timing.